Ex­clu­sive: Helsinn chief Ric­car­do Braglia spells out a block­buster plan to take the fam­i­ly phar­ma pub­lic — with an eye on new can­cer drug deals, spin­out

Late on Fri­day, as the bio­phar­ma in­dus­try in the US was mak­ing a rush to the ex­its for a 3-day week­end, Bridge­Bio put out word that the FDA had come through on a crit­i­cal first OK for QED, one of their many subs push­ing a drug through clin­i­cal de­vel­op­ment. The agency of­fered an ac­cel­er­at­ed ap­proval for Trusel­tiq (in­fi­gra­tinib), a new ther­a­py for cas­es of cholan­gio­car­ci­no­ma har­bor­ing an FGFR2 fu­sion or re­arrange­ment.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE